Combioxin SA
Drug development against severe infections
Combioxin is a Swiss-based biotechnology company dedicated to the development of first-in-class life-saving drugs for severe infections.
The company is currently running two parallel programs on an innovative technology designed to fight severe bacterial and viral infections.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
16.06.2023
FDA grants extended exclusivity for bacterial pneumonia treatment (startupticker.ch)
27.08.2021
Combioxin enters into licensing agreement for its treatment against severe pneumonia (startupticker.ch)
03.05.2019
Combioxin announces milestone in the field of infectious diseases (startupticker.ch)
17.04.2018
Positive results from first-in-man trial for the treatment of Pneumonia (startupticker.ch)
No milestones
No Jobs
No videos and documents
Combioxin SA
Drug development against severe infections
Website:
www.combioxin.com/
Headquarter:
Epalinges
Foundation Date:
September 2015
Technology:
- Biotech